Metformin
5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
5
Ongoing
3
Recruiting
1
Completed
2
Sites
26
Countries
2
Endpoints
32
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 32 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 7 of 32 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
6
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
5 of 5
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| MAPMetformin in Alzheimer's Dementia Prevention | Metformin Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2/3 | Active, not recruiting | 22 | Apr 2026 | 1 | |
| AD-SMARTAn Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease | Atomoxetine, Metformin Alzheimer’s disease, MCI / preclinical Alzheimer’s | Multiple dementia etiologies | Ph 3 | Recruiting | 2 | - | - | |
| MCIMetformin in Amnestic Mild Cognitive Impairment | Metformin Alzheimer’s disease, MCI / preclinical Alzheimer’s | Age 55-90 | Ph 2 | Completed | 1 | Feb 2012 | 1 | results |
| NCT01965756Effect of Insulin Sensitizer Metformin on AD Biomarkers | Metformin Alzheimer’s disease, Vascular cognitive impairment / dementia | Amyloid biomarker required (PET/CSF) | Ph 2 | Completed | 1 | Dec 2015 | 1 | results |
| NCT04220021Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD | Metformin Frontotemporal dementia | Age 18-80 | Ph 2 | Active, not recruiting | 1 | Aug 2024 | 7 | results |
Showing 1-5 of 5 trials